Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Non-prescription Drugs market report explains the definition, types, applications, major countries, and major players of the Non-prescription Drugs market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Novartis
Eli Lilly
Shire
Bayer
Gilead Sciences
Novo Nordisk
Amgen
Allergan
Sanofi
Merck & Co (MSD)
AstraZeneca
Bristol-Myers Squibb
AbbVie
Boehringer Ingelheim
Teva
Roche
Pfizer
GlaxoSmithKline (GSK)
Takeda
Johnson & Johnson
By Type:
Brand Drugs
Generic Drug
By End-User:
Hospital
Clinic
Other
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Non-prescription Drugs Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Non-prescription Drugs Outlook to 2028- Original Forecasts
-
2.2 Non-prescription Drugs Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Non-prescription Drugs Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Non-prescription Drugs Market- Recent Developments
-
6.1 Non-prescription Drugs Market News and Developments
-
6.2 Non-prescription Drugs Market Deals Landscape
7 Non-prescription Drugs Raw Materials and Cost Structure Analysis
-
7.1 Non-prescription Drugs Key Raw Materials
-
7.2 Non-prescription Drugs Price Trend of Key Raw Materials
-
7.3 Non-prescription Drugs Key Suppliers of Raw Materials
-
7.4 Non-prescription Drugs Market Concentration Rate of Raw Materials
-
7.5 Non-prescription Drugs Cost Structure Analysis
-
7.5.1 Non-prescription Drugs Raw Materials Analysis
-
7.5.2 Non-prescription Drugs Labor Cost Analysis
-
7.5.3 Non-prescription Drugs Manufacturing Expenses Analysis
8 Global Non-prescription Drugs Import and Export Analysis (Top 10 Countries)
-
8.1 Global Non-prescription Drugs Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Non-prescription Drugs Export by Region (Top 10 Countries) (2017-2028)
9 Global Non-prescription Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Non-prescription Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Brand Drugs Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Generic Drug Consumption and Growth Rate (2017-2022)
-
9.2 Global Non-prescription Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Other Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Non-prescription Drugs Market Analysis and Outlook till 2022
-
10.1 Global Non-prescription Drugs Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Non-prescription Drugs Consumption (2017-2022)
-
10.2.2 Canada Non-prescription Drugs Consumption (2017-2022)
-
10.2.3 Mexico Non-prescription Drugs Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Non-prescription Drugs Consumption (2017-2022)
-
10.3.2 UK Non-prescription Drugs Consumption (2017-2022)
-
10.3.3 Spain Non-prescription Drugs Consumption (2017-2022)
-
10.3.4 Belgium Non-prescription Drugs Consumption (2017-2022)
-
10.3.5 France Non-prescription Drugs Consumption (2017-2022)
-
10.3.6 Italy Non-prescription Drugs Consumption (2017-2022)
-
10.3.7 Denmark Non-prescription Drugs Consumption (2017-2022)
-
10.3.8 Finland Non-prescription Drugs Consumption (2017-2022)
-
10.3.9 Norway Non-prescription Drugs Consumption (2017-2022)
-
10.3.10 Sweden Non-prescription Drugs Consumption (2017-2022)
-
10.3.11 Poland Non-prescription Drugs Consumption (2017-2022)
-
10.3.12 Russia Non-prescription Drugs Consumption (2017-2022)
-
10.3.13 Turkey Non-prescription Drugs Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Non-prescription Drugs Consumption (2017-2022)
-
10.4.2 Japan Non-prescription Drugs Consumption (2017-2022)
-
10.4.3 India Non-prescription Drugs Consumption (2017-2022)
-
10.4.4 South Korea Non-prescription Drugs Consumption (2017-2022)
-
10.4.5 Pakistan Non-prescription Drugs Consumption (2017-2022)
-
10.4.6 Bangladesh Non-prescription Drugs Consumption (2017-2022)
-
10.4.7 Indonesia Non-prescription Drugs Consumption (2017-2022)
-
10.4.8 Thailand Non-prescription Drugs Consumption (2017-2022)
-
10.4.9 Singapore Non-prescription Drugs Consumption (2017-2022)
-
10.4.10 Malaysia Non-prescription Drugs Consumption (2017-2022)
-
10.4.11 Philippines Non-prescription Drugs Consumption (2017-2022)
-
10.4.12 Vietnam Non-prescription Drugs Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Non-prescription Drugs Consumption (2017-2022)
-
10.5.2 Colombia Non-prescription Drugs Consumption (2017-2022)
-
10.5.3 Chile Non-prescription Drugs Consumption (2017-2022)
-
10.5.4 Argentina Non-prescription Drugs Consumption (2017-2022)
-
10.5.5 Venezuela Non-prescription Drugs Consumption (2017-2022)
-
10.5.6 Peru Non-prescription Drugs Consumption (2017-2022)
-
10.5.7 Puerto Rico Non-prescription Drugs Consumption (2017-2022)
-
10.5.8 Ecuador Non-prescription Drugs Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Non-prescription Drugs Consumption (2017-2022)
-
10.6.2 Kuwait Non-prescription Drugs Consumption (2017-2022)
-
10.6.3 Oman Non-prescription Drugs Consumption (2017-2022)
-
10.6.4 Qatar Non-prescription Drugs Consumption (2017-2022)
-
10.6.5 Saudi Arabia Non-prescription Drugs Consumption (2017-2022)
-
10.6.6 United Arab Emirates Non-prescription Drugs Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Non-prescription Drugs Consumption (2017-2022)
-
10.7.2 South Africa Non-prescription Drugs Consumption (2017-2022)
-
10.7.3 Egypt Non-prescription Drugs Consumption (2017-2022)
-
10.7.4 Algeria Non-prescription Drugs Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Non-prescription Drugs Consumption (2017-2022)
-
10.8.2 New Zealand Non-prescription Drugs Consumption (2017-2022)
11 Global Non-prescription Drugs Competitive Analysis
-
11.1 Novartis
-
11.1.1 Novartis Company Details
-
11.1.2 Novartis Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Novartis Non-prescription Drugs Main Business and Markets Served
-
11.1.4 Novartis Non-prescription Drugs Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Eli Lilly
-
11.2.1 Eli Lilly Company Details
-
11.2.2 Eli Lilly Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Eli Lilly Non-prescription Drugs Main Business and Markets Served
-
11.2.4 Eli Lilly Non-prescription Drugs Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Shire
-
11.3.1 Shire Company Details
-
11.3.2 Shire Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Shire Non-prescription Drugs Main Business and Markets Served
-
11.3.4 Shire Non-prescription Drugs Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Bayer
-
11.4.1 Bayer Company Details
-
11.4.2 Bayer Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Bayer Non-prescription Drugs Main Business and Markets Served
-
11.4.4 Bayer Non-prescription Drugs Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Gilead Sciences
-
11.5.1 Gilead Sciences Company Details
-
11.5.2 Gilead Sciences Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Gilead Sciences Non-prescription Drugs Main Business and Markets Served
-
11.5.4 Gilead Sciences Non-prescription Drugs Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Novo Nordisk
-
11.6.1 Novo Nordisk Company Details
-
11.6.2 Novo Nordisk Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Novo Nordisk Non-prescription Drugs Main Business and Markets Served
-
11.6.4 Novo Nordisk Non-prescription Drugs Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Amgen
-
11.7.1 Amgen Company Details
-
11.7.2 Amgen Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Amgen Non-prescription Drugs Main Business and Markets Served
-
11.7.4 Amgen Non-prescription Drugs Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Allergan
-
11.8.1 Allergan Company Details
-
11.8.2 Allergan Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Allergan Non-prescription Drugs Main Business and Markets Served
-
11.8.4 Allergan Non-prescription Drugs Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Sanofi
-
11.9.1 Sanofi Company Details
-
11.9.2 Sanofi Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Sanofi Non-prescription Drugs Main Business and Markets Served
-
11.9.4 Sanofi Non-prescription Drugs Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Merck & Co (MSD)
-
11.10.1 Merck & Co (MSD) Company Details
-
11.10.2 Merck & Co (MSD) Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Merck & Co (MSD) Non-prescription Drugs Main Business and Markets Served
-
11.10.4 Merck & Co (MSD) Non-prescription Drugs Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 AstraZeneca
-
11.11.1 AstraZeneca Company Details
-
11.11.2 AstraZeneca Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 AstraZeneca Non-prescription Drugs Main Business and Markets Served
-
11.11.4 AstraZeneca Non-prescription Drugs Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Bristol-Myers Squibb
-
11.12.1 Bristol-Myers Squibb Company Details
-
11.12.2 Bristol-Myers Squibb Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Bristol-Myers Squibb Non-prescription Drugs Main Business and Markets Served
-
11.12.4 Bristol-Myers Squibb Non-prescription Drugs Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 AbbVie
-
11.13.1 AbbVie Company Details
-
11.13.2 AbbVie Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 AbbVie Non-prescription Drugs Main Business and Markets Served
-
11.13.4 AbbVie Non-prescription Drugs Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Boehringer Ingelheim
-
11.14.1 Boehringer Ingelheim Company Details
-
11.14.2 Boehringer Ingelheim Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Boehringer Ingelheim Non-prescription Drugs Main Business and Markets Served
-
11.14.4 Boehringer Ingelheim Non-prescription Drugs Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 Teva
-
11.15.1 Teva Company Details
-
11.15.2 Teva Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 Teva Non-prescription Drugs Main Business and Markets Served
-
11.15.4 Teva Non-prescription Drugs Product Portfolio
-
11.15.5 Recent Research and Development Strategies
-
11.16 Roche
-
11.16.1 Roche Company Details
-
11.16.2 Roche Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.16.3 Roche Non-prescription Drugs Main Business and Markets Served
-
11.16.4 Roche Non-prescription Drugs Product Portfolio
-
11.16.5 Recent Research and Development Strategies
-
11.17 Pfizer
-
11.17.1 Pfizer Company Details
-
11.17.2 Pfizer Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.17.3 Pfizer Non-prescription Drugs Main Business and Markets Served
-
11.17.4 Pfizer Non-prescription Drugs Product Portfolio
-
11.17.5 Recent Research and Development Strategies
-
11.18 GlaxoSmithKline (GSK)
-
11.18.1 GlaxoSmithKline (GSK) Company Details
-
11.18.2 GlaxoSmithKline (GSK) Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.18.3 GlaxoSmithKline (GSK) Non-prescription Drugs Main Business and Markets Served
-
11.18.4 GlaxoSmithKline (GSK) Non-prescription Drugs Product Portfolio
-
11.18.5 Recent Research and Development Strategies
-
11.19 Takeda
-
11.19.1 Takeda Company Details
-
11.19.2 Takeda Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.19.3 Takeda Non-prescription Drugs Main Business and Markets Served
-
11.19.4 Takeda Non-prescription Drugs Product Portfolio
-
11.19.5 Recent Research and Development Strategies
-
11.20 Johnson & Johnson
-
11.20.1 Johnson & Johnson Company Details
-
11.20.2 Johnson & Johnson Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
11.20.3 Johnson & Johnson Non-prescription Drugs Main Business and Markets Served
-
11.20.4 Johnson & Johnson Non-prescription Drugs Product Portfolio
-
11.20.5 Recent Research and Development Strategies
12 Global Non-prescription Drugs Market Outlook by Types and Applications to 2028
-
12.1 Global Non-prescription Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Brand Drugs Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Generic Drug Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Non-prescription Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Non-prescription Drugs Market Analysis and Outlook to 2028
-
13.1 Global Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.2.2 Canada Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.2.3 Mexico Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.3.2 UK Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.3.3 Spain Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.3.4 Belgium Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.3.5 France Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.3.6 Italy Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.3.7 Denmark Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.3.8 Finland Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.3.9 Norway Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.3.10 Sweden Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.3.11 Poland Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.3.12 Russia Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.3.13 Turkey Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.4.2 Japan Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.4.3 India Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.4.4 South Korea Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.4.8 Thailand Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.4.9 Singapore Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.4.11 Philippines Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.5.2 Colombia Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.5.3 Chile Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.5.4 Argentina Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.5.6 Peru Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.6.3 Oman Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.6.4 Qatar Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.7.2 South Africa Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.7.3 Egypt Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.7.4 Algeria Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Non-prescription Drugs Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Non-prescription Drugs Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Non-prescription Drugs
-
Figure of Non-prescription Drugs Picture
-
Table Global Non-prescription Drugs Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Non-prescription Drugs Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Brand Drugs Consumption and Growth Rate (2017-2022)
-
Figure Global Generic Drug Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Other Consumption and Growth Rate (2017-2022)
-
Figure Global Non-prescription Drugs Consumption by Country (2017-2022)
-
Table North America Non-prescription Drugs Consumption by Country (2017-2022)
-
Figure United States Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Canada Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Mexico Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Non-prescription Drugs Consumption by Country (2017-2022)
-
Figure Germany Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure UK Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Spain Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Belgium Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure France Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Italy Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Denmark Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Finland Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Norway Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Sweden Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Poland Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Russia Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Turkey Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Table APAC Non-prescription Drugs Consumption by Country (2017-2022)
-
Figure China Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Thailand Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Singapore Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Philippines Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Table South America Non-prescription Drugs Consumption by Country (2017-2022)
-
Figure Brazil Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Colombia Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Chile Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Argentina Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Peru Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Table GCC Non-prescription Drugs Consumption by Country (2017-2022)
-
Figure Bahrain Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Oman Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Qatar Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Table Africa Non-prescription Drugs Consumption by Country (2017-2022)
-
Figure Nigeria Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Africa Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Egypt Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure Algeria Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Table Oceania Non-prescription Drugs Consumption by Country (2017-2022)
-
Figure Australia Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Non-prescription Drugs Consumption and Growth Rate (2017-2022)
-
Table Novartis Company Details
-
Table Novartis Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Non-prescription Drugs Main Business and Markets Served
-
Table Novartis Non-prescription Drugs Product Portfolio
-
Table Eli Lilly Company Details
-
Table Eli Lilly Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly Non-prescription Drugs Main Business and Markets Served
-
Table Eli Lilly Non-prescription Drugs Product Portfolio
-
Table Shire Company Details
-
Table Shire Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Shire Non-prescription Drugs Main Business and Markets Served
-
Table Shire Non-prescription Drugs Product Portfolio
-
Table Bayer Company Details
-
Table Bayer Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer Non-prescription Drugs Main Business and Markets Served
-
Table Bayer Non-prescription Drugs Product Portfolio
-
Table Gilead Sciences Company Details
-
Table Gilead Sciences Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Gilead Sciences Non-prescription Drugs Main Business and Markets Served
-
Table Gilead Sciences Non-prescription Drugs Product Portfolio
-
Table Novo Nordisk Company Details
-
Table Novo Nordisk Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novo Nordisk Non-prescription Drugs Main Business and Markets Served
-
Table Novo Nordisk Non-prescription Drugs Product Portfolio
-
Table Amgen Company Details
-
Table Amgen Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amgen Non-prescription Drugs Main Business and Markets Served
-
Table Amgen Non-prescription Drugs Product Portfolio
-
Table Allergan Company Details
-
Table Allergan Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Allergan Non-prescription Drugs Main Business and Markets Served
-
Table Allergan Non-prescription Drugs Product Portfolio
-
Table Sanofi Company Details
-
Table Sanofi Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi Non-prescription Drugs Main Business and Markets Served
-
Table Sanofi Non-prescription Drugs Product Portfolio
-
Table Merck & Co (MSD) Company Details
-
Table Merck & Co (MSD) Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck & Co (MSD) Non-prescription Drugs Main Business and Markets Served
-
Table Merck & Co (MSD) Non-prescription Drugs Product Portfolio
-
Table AstraZeneca Company Details
-
Table AstraZeneca Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Non-prescription Drugs Main Business and Markets Served
-
Table AstraZeneca Non-prescription Drugs Product Portfolio
-
Table Bristol-Myers Squibb Company Details
-
Table Bristol-Myers Squibb Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Non-prescription Drugs Main Business and Markets Served
-
Table Bristol-Myers Squibb Non-prescription Drugs Product Portfolio
-
Table AbbVie Company Details
-
Table AbbVie Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table AbbVie Non-prescription Drugs Main Business and Markets Served
-
Table AbbVie Non-prescription Drugs Product Portfolio
-
Table Boehringer Ingelheim Company Details
-
Table Boehringer Ingelheim Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim Non-prescription Drugs Main Business and Markets Served
-
Table Boehringer Ingelheim Non-prescription Drugs Product Portfolio
-
Table Teva Company Details
-
Table Teva Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Non-prescription Drugs Main Business and Markets Served
-
Table Teva Non-prescription Drugs Product Portfolio
-
Table Roche Company Details
-
Table Roche Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche Non-prescription Drugs Main Business and Markets Served
-
Table Roche Non-prescription Drugs Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Non-prescription Drugs Main Business and Markets Served
-
Table Pfizer Non-prescription Drugs Product Portfolio
-
Table GlaxoSmithKline (GSK) Company Details
-
Table GlaxoSmithKline (GSK) Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline (GSK) Non-prescription Drugs Main Business and Markets Served
-
Table GlaxoSmithKline (GSK) Non-prescription Drugs Product Portfolio
-
Table Takeda Company Details
-
Table Takeda Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Takeda Non-prescription Drugs Main Business and Markets Served
-
Table Takeda Non-prescription Drugs Product Portfolio
-
Table Johnson & Johnson Company Details
-
Table Johnson & Johnson Non-prescription Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Johnson & Johnson Non-prescription Drugs Main Business and Markets Served
-
Table Johnson & Johnson Non-prescription Drugs Product Portfolio
-
Figure Global Brand Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Generic Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Other Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Non-prescription Drugs Consumption Forecast by Country (2022-2028)
-
Table North America Non-prescription Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Non-prescription Drugs Consumption Forecast by Country (2022-2028)
-
Figure Germany Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Non-prescription Drugs Consumption Forecast by Country (2022-2028)
-
Figure China Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Non-prescription Drugs Consumption Forecast by Country (2022-2028)
-
Figure Brazil Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Non-prescription Drugs Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Non-prescription Drugs Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Non-prescription Drugs Consumption Forecast by Country (2022-2028)
-
Figure Australia Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Non-prescription Drugs Consumption Forecast and Growth Rate (2022-2028)
-
